| Name | Title | Contact Details |
|---|
JERA Americas is supporting an energy transition in an environmentally and socially responsible manner. The Company is a subsidiary of Tokyo-based JERA, which stands for Japans Energy for a New Era. JERA has committed to achieving net zero CO2 emissions from its businesses by 2050 and is contributing to the development of a sustainable society.
Boardwalk Real Property Management is a San Antonio, TX-based company in the Business Services sector.
Jet Metal Corp (TSX.V: JET) (OTCQB: JETMF) ("Jet Metal") is a uranium and vanadium explorer and developer with projects across North America. Its CMB Uranium/Vanadium Project, located in Newfoundland and Labrador, Canada, encompasses the Two Time Zone, which as an Indicated uranium resource estimate of 2.33 M lbs (1.82 M tonnes @0.058% U3O8) and an Inferred uranium resource estimate of 3.373 M lbs (3.16 M tonnes @0.053% U3O8). Additional information about the CMB Uranium-Vandium Project can be found in the technical report filed on SEDAR at www.sedar.com entitled: “Technical Report on the CMBNW Property, Newfoundland and Labrador, Canada: prepared for Jet Metal (formerly Crosshair Exploration and Mining) and Silver Spruce Resources dated June 22, 2009. In addition to the CMB Project, Jet Metal's Bootheel Project is located in uranium mining friendly Wyoming and has the potential to be mined using in-situ recovery methods. Wyoming has the largest known uranium ore reserves in the United States and currently leads the U.S. in uranium production. Stewart Wallis, P.Geo., is a Director of the Company and a Qualified Person as defined by National Instrument 43-101 for the above mentioned projects. The QP is a member in good standing of the Association of Professional Engineers and Geoscientists of British Columbia (APEGBC) as a registered Professional Geoscientist (P.Geo.).
DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Over the course of three decades, we have been a trusted partner of royalty sellers and demonstrated strong execution, building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. That foundation sets us apart as we continue developing solutions for innovators while building and managing a risk-mitigated portfolio of therapeutic assets that generates attractive returns and growth potential for investors. We have deployed more than $2.5 billion, acquiring more than 70 royalties on 40-plus drugs.